P1064 Upadacitinib is safe and effective in Ulcerative Colitis patients with prior exposure to Tofacitinib
Robert Gilmore(The University of Queensland), Jakob Begun(Translational Research Institute), Daniel Lightowler(The University of Western Australia), Rupert W. Leong(The University of Sydney), Imogen Hartley(St Vincent's Hospital Melbourne), Britt Christensen(The Royal Melbourne Hospital), Gillian Mahy(Townsville Hospital), Soobee Kim(Fiona Stanley Hospital), Nik S. Ding(The University of Melbourne), Samuel Han(University of Colorado Anschutz Medical Campus), Yoon‐Kyo An(Mater Hospital), Richard Fernandes(The University of Queensland), Gregory Moore(Monash Medical Centre), Jonathan Segal(The Royal Melbourne Hospital), Jack West(The Royal Melbourne Hospital), Arteen Arzivian(Macquarie University), Tessa Greeve(Monash Health), Aditya Mithanthaya(Royal Perth Hospital), K Venugpal(Royal Perth Hospital), B. L. Andrew(Eastern Health), Robert G. Bryant(University of Sheffield), Arjun Singh(Fiona Stanley Hospital), Anil Vasudevan(College of Medicine & JNM Hospital)
Cited by 2
Related Papers
Histologic Normalization Occurs in Ulcerative Colitis and Is Associated With Improved Clinical Outcomes
|Clinical Gastroenterology and Hepatology|2017|234
Genome-wide association study for Crohn's disease in the Quebec Founder Population identifies multiple validated disease loci
|Proceedings of the National Academy of Sciences|2007|219
Deep Resequencing of GWAS Loci Identifies Rare Variants in CARD9, IL23R and RNF186 That Are Associated with Ulcerative Colitis
|PLoS Genetics|2013|217
Clinical and Laboratory Comparison of Botulism from Toxin Types A, B, and E in the United States, 1975-1988
|The Journal of Infectious Diseases|1992|217